Abstract
Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 12-33 |
| Number of pages | 22 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 5 |
| Issue number | 1 |
| State | Published - Jan 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- 5-HT3 receptor antagonists
- Anticipatory emesis
- Antiemesis
- Aprepitant
- Chemotherapy-induced emesis
- Nausea and vomiting
- NCCN Clinical Practice Guidelines
- NK-1-receptor antagonists
- Palonosetron
- Radiation-induced emesis
ASJC Scopus subject areas
- Oncology
Cite this
Antiemesis : Clinical practice guidelines in Oncology™. / Ettinger, David S; Bierman, Philip J.; Bradbury, Bob; Comish, Carli C.; Ellis, Georgiana; Ignoffo, Robert J.; Kirkegaard, Steve; Kloth, Dwight D.; Kris, Mark G.; Lim, Dean; Markiewicz, Michael Anne; McNulty, Robert; Nabati, Lidia; Todaro, Barbara; Urba, Susan; Yowell, Sally.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 1, 01.2007, p. 12-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiemesis
T2 - Clinical practice guidelines in Oncology™
AU - Ettinger, David S
AU - Bierman, Philip J.
AU - Bradbury, Bob
AU - Comish, Carli C.
AU - Ellis, Georgiana
AU - Ignoffo, Robert J.
AU - Kirkegaard, Steve
AU - Kloth, Dwight D.
AU - Kris, Mark G.
AU - Lim, Dean
AU - Markiewicz, Michael Anne
AU - McNulty, Robert
AU - Nabati, Lidia
AU - Todaro, Barbara
AU - Urba, Susan
AU - Yowell, Sally
PY - 2007/1
Y1 - 2007/1
N2 - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
AB - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
KW - 5-HT3 receptor antagonists
KW - Anticipatory emesis
KW - Antiemesis
KW - Aprepitant
KW - Chemotherapy-induced emesis
KW - Nausea and vomiting
KW - NCCN Clinical Practice Guidelines
KW - NK-1-receptor antagonists
KW - Palonosetron
KW - Radiation-induced emesis
UR - http://www.scopus.com/inward/record.url?scp=33846786930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846786930&partnerID=8YFLogxK
M3 - Article
C2 - 17239323
AN - SCOPUS:33846786930
VL - 5
SP - 12
EP - 33
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
SN - 1540-1405
IS - 1
ER -